DDB2 and malignant colon neoplasm: Low DDB2 levels predict a significantly better survival when stratifying tumors by DDB2 expression in all 108 oxaliplatin-treated colon cancer patients irrespectively of TNM (Figure 5A and Supplementary Figure S7c).